{"id":{"repo_id":"adelaide","oai_identifier":"oai:digital.library.adelaide.edu.au:2440/150672"},"canonical_url":"https://search.dev.ndltd.org/etd/adelaide/oai:digital.library.adelaide.edu.au:2440/150672","repository":{"repo_id":"adelaide","name":"University of Adelaide","base_url":"https://digital.library.adelaide.edu.au/server/oai/request"},"display":{"title":"Investigating G-protein coupled receptors as novel biomarkers for diagnosis, prognosis, and targeted therapy in ovarian cancer","abstract":"This research project is a first step towards the future generation of a nanomedicine platform driven by the identification of GPCRs as tumour specific biomarkers. It can be very well imagined that an array of frequently overexpressed GPCRs – matched to ovarian tumour heterogeneity – will in a first step be implemented as a diagnostic tool. In a second step targeted drug carriers could be selected depending on GPCR expression profiles leading to personalised treatment. In summary, this work highlights the theranostic potential of GPCRs, which could lead to a translational framework, combining diagnostics and receptor biology, with nanotechnology. Future work will contribute to the rapidly expanding field of precision oncology and may improve patient outcomes.","abstract_html":"This research project is a first step towards the future generation of a nanomedicine platform driven by the identification of GPCRs as tumour specific biomarkers. It can be very well imagined that an array of frequently overexpressed GPCRs – matched to ovarian tumour heterogeneity – will in a first step be implemented as a diagnostic tool. In a second step targeted drug carriers could be selected depending on GPCR expression profiles leading to personalised treatment. In summary, this work highlights the theranostic potential of GPCRs, which could lead to a translational framework, combining diagnostics and receptor biology, with nanotechnology. Future work will contribute to the rapidly expanding field of precision oncology and may improve patient outcomes.","abstract_has_math":false,"creators":["Khetan, Riya"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Albrecht, Hugo"],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-12-11","date_published":"2025-12-11","updated_at":"2026-07-24T00:50:59Z","subjects":["ovarian cancer","drug delivery","G-protein coupled receptors"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2440/150672","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Albrecht, Hugo"]},{"key":"dc:creator","label":"Author","values":["Khetan, Riya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2025-12-11"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["ovarian cancer","drug delivery","G-protein coupled receptors"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2440/150672"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This research project is a first step towards the future generation of a nanomedicine platform driven by the identification of GPCRs as tumour specific biomarkers. It can be very well imagined that an array of frequently overexpressed GPCRs – matched to ovarian tumour heterogeneity – will in a first step be implemented as a diagnostic tool. In a second step targeted drug carriers could be selected depending on GPCR expression profiles leading to personalised treatment. In summary, this work highlights the theranostic potential of GPCRs, which could lead to a translational framework, combining diagnostics and receptor biology, with nanotechnology. Future work will contribute to the rapidly expanding field of precision oncology and may improve patient outcomes."]},{"key":"dc:title","label":"Title","values":["Investigating G-protein coupled receptors as novel biomarkers for diagnosis, prognosis, and targeted therapy in ovarian cancer"]}]}],"canonical_facts":{"dc:contributor.advisor":["Albrecht, Hugo"],"dc:creator":["Khetan, Riya"],"dc:date.issued":["2025-12-11"],"dc:description.abstract":["This research project is a first step towards the future generation of a nanomedicine platform driven by the identification of GPCRs as tumour specific biomarkers. It can be very well imagined that an array of frequently overexpressed GPCRs – matched to ovarian tumour heterogeneity – will in a first step be implemented as a diagnostic tool. In a second step targeted drug carriers could be selected depending on GPCR expression profiles leading to personalised treatment. In summary, this work highlights the theranostic potential of GPCRs, which could lead to a translational framework, combining diagnostics and receptor biology, with nanotechnology. Future work will contribute to the rapidly expanding field of precision oncology and may improve patient outcomes."],"dc:identifier.uri":["https://hdl.handle.net/2440/150672"],"dc:language.iso":["en"],"dc:subject":["ovarian cancer","drug delivery","G-protein coupled receptors"],"dc:title":["Investigating G-protein coupled receptors as novel biomarkers for diagnosis, prognosis, and targeted therapy in ovarian cancer"],"dc:type":["Thesis"]},"updated_at":"2026-07-24T00:50:59Z"}